Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 94 clinical trials
Catastrophism in Chronic Inflammatory Rheumatism

in the pain experience in patients who are catastrophic. In chronic inflammatory rheumatic diseases such as rheumatoid arthritis, spondyloarthritis and psoriatic arthritis, the prevalence and

  • 0 views
  • 24 Jan, 2021
  • 2 locations
Safety and Pharmacokinetics of JAK/ROCK Inhibitor in Healthy Volunteers

emerged as a new option for the treatment of various inflammatory diseases, including rheumatoid arthritis, psoriatic arthritis, spondyloarthritis, skin disorders and others. CPL409116 inhibits JAK1 and

  • 0 views
  • 27 Jan, 2021
  • 1 location
Rotation or Change of Biotherapy After TNF Blocker Treatment Failure for Axial Spondyloarthritis

will follow the "Treat-to-Target" principle. This approach already demonstrated its benefit in rheumatoid arthritis or in psoriatic arthritis. This concept was also suggested for axSpA with low levels

il-23
NSAID
rheumatoid arthritis
tumor necrosis factor
enthesitis
  • 17 views
  • 25 Jan, 2021
  • 26 locations
Spondyloarthritis: Inducing Drug-free Remission by Early TNF-alpha Blockade

The SPARTACUS study will explore the therapeutic efficacy of 2 different treatment strategies for patients suffering from peripheral Spondyloarthritis (pSpA), classified according to the "Assessment in SpondyloArthritis international Society" (ASAS) classification criteria; it will be set up as a 48-week, prospective, randomized, active-comparator controlled, double-blind, double-dummy, clinical trial with a …

  • 0 views
  • 24 Feb, 2021
  • 6 locations
Evaluating Safety & Efficacy of Apremilast in the Treatment of Cutaneous Disease in Patients With Recalcitrant Dermatomyositis

With limited treatment options available for dermatomyositis, the investigators hypothesize that apremilast, a phosphodiesterase-4 (PDE-4) inhibitor, is a safe and efficacious add-on treatment in patients with refractory cutaneous dermatomyositis. The study will investigate the efficacy, safety and toxicity of apremilast given at 30 mg twice daily to patients with refractory …

  • 2 views
  • 18 Feb, 2021
  • 1 location
Psoriatic Arthritis D2P Screening

The overarching goal of this study is to develop a direct-to-patient screening approach that will improve early Psoriatic Arthritis (PsA) detection in patients with psoriasis. Previously

arthritis
psoriasis
psa screening
  • 42 views
  • 25 Jan, 2021
  • 2 locations
A Study to Evaluate the Impact of Apremilast (CC-10004) on MRI Outcomes in Subjects With Psoriatic Arthritis

This is a Phase 4, multicenter, single-arm, open-label study to evaluate the impact of apremilast, either in monotherapy or with stable Methotrexate (MTX), on Magnetic resonance imaging (MRI) outcomes in subjects with active PsA with up to 5 years of disease duration (since diagnosis).

glucocorticoids
methotrexate
NSAID
apremilast
tumor necrosis factor
  • 190 views
  • 26 Jan, 2021
  • 99 locations
A Study to Evaluate the Efficacy and Safety of Bimekizumab in the Treatment of Subjects With Active Psoriatic Arthritis

alpha-inadequate responders (TNF-IR) subjects with active Psoriatic Arthritis (PsA).

rheumatoid factor
psoriasis
bimekizumab
methotrexate
NSAID
  • 428 views
  • 03 Feb, 2021
  • 210 locations
A Study to Test the Efficacy and Safety of Bimekizumab in the Treatment of Subjects With Active Psoriatic Arthritis

Psoriatic Arthritis (PsA).

adalimumab
arthritis
rheumatoid factor
psoriasis
hydroxychloroquine
  • 235 views
  • 04 Mar, 2021
  • 308 locations
Study to Demonstrate the Efficacy Safety and Tolerability of Intravenous Secukinumab up to 52 Weeks in Subjects With Active Psoriatic Arthritis

thereafter with 3 mg/kg administered every four weeks) in patients with active psoriatic arthritis (PsA) despite current or previous NSAID, DMARD and/or anti-TNF therapy.

puva
rheumatoid factor
psoriasis
NSAID
tumor necrosis factor
  • 84 views
  • 26 Jan, 2021
  • 47 locations